1 October 2024 - The October 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The October issue of the Schedule includes several new/revised listings of note:

• Adalimumab (Humira, Yuflyma) - new formulation
• Aflibercept (Eylea) - new formulation
• Avacopan (Tavneos) - new medicine
• Bevacizumab (Vegzelma) - new biosimilar medicine
• Bimekizumab (Bimzelx) - new indications
• Etrasimod arginine (Velsipity) - new medicine
• Ibrutinib (Imbruvica) - new indication
• Icosapent ethyl (Vazkepa) - new medicine
• Lenalidomide (Lenalide) - new strength
• Mepolizumab (Nucala) - restriction change
• Siponimod hemifumarate (Mayzent) - new strength
• Vedolizumab (Entyvio) - Restriction change

Read Summary of PBS changes